Evidence map›Paper›PMID 38170382›Full record

ArticleMedical oncology (Northwood, London, England)2024

Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway.

Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Shuqi Wei, Ai Li, Li Wang, Xiangqiu Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Donglin Sun *Department of Urology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518100, China.
Jing Guo *Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510000, China.
Weifei Liang *Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, 511500, Guangdong, China.
Yangxiao ChenAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510000, China.
Shuqi WeiAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510000, China.
Ai LiDepartment of Clinical Medicine, The Second Clinical School of Guangzhou Medical University, Guangzhou, China.
Li WangNephrology Department, Southern Medical University Affiliated Longhua People's Hospital, Shenzhen, China. 13632908171@163.com.
Xiangqiu ChenDepartment of Urology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518100, China. chxq0301@smu.edu.cn.ORCID http://orcid.org/0000-0001-8432-5299
Guangzhou Medical University · CNSouthern Medical University Shenzhen Hospital · CNSecond Affiliated Hospital of Guangzhou Medical University · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

Shenzhen Fundamental Research Program CYJ20190808095615389
6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the most common malignant tumors that exhibit both chemoresistance and recurrence. SUV39H2 is highly expressed in many types of human tumors, but its role in the development and progression of PCa has never been clarified. The aim of this study is to elucidate the role of SUV39H2 in the development and progression of PCa, its association with the AKT/FOXO signaling pathway, and its potential implications for PCa diagnosis and treatment. SUV39H2 expression was analyzed in The Cancer Genome Atlas (TCGA) and genotype tissue expression pan-cancer data. The TCGA database was evaluated for SUV39H2 enrichment and its correlation to immune cell infiltration. SUV39H2 levels in PCa tissues and control tissues were determined in 30 patients using qPCR and IHC. Clinical relevance was assessed via The Cancer Genome Atlas (TCGA). In vitro assessments including colony formation assays, Western Blot analysis, CCK-8 assays, and flow cytometry were utilized to establish SUV39H2's contribution to PCa cell growth. The influence of SUV39H2 on PC3 and DU145 cell proliferation was assessed through a cell line-derived xenograft model. Sphere formation assays and qPCR were employed to delineate SUV39H2's role in PCa stemness and chemosensitivity. In vitro macrophage polarization assays provided insights into SUV39H2's association with M2 macrophages, while enrichment analysis shed light on its role in FOXO signaling. PCa tissues expressed higher levels of SUV39H2 than normal tissues. By knocking down SUV39H2, PCa cells were made more chemosensitive to docetaxel and cell proliferation and stemness were inhibited. Additionally, SUV39H2 knockdown significantly inhibited in vivo PCa cell growth and inhibited the polarization of macrophages. Furthermore, SUV39H2 was found to regulate AKT/FOXO signaling by increasing Akt and FOXO3a phosphorylation. Our findings highlight SUV39H2's role in PCa cell apoptosis and chemosensitivity mainly by regulating the AKT/FOXO signaling pathway and suggest that SUV39H2 could be a potential target for PCa diagnosis and treatment.

Indexed as

Prostatic NeoplasmsProto-Oncogene Proteins c-aktApoptosisCell Line, TumorCell ProliferationHistone-Lysine N-MethyltransferaseHistone MethyltransferasesHumansMaleSignal TransductionHistone-Lysine N-MethyltransferaseHistone MethyltransferasesProto-Oncogene Proteins c-aktSUV39H2 protein, humanAKT/FOXO signalingApoptosisCancer stem cellPCaSUV39H2

Identifiers

PMID38170382
OpenAlexW4390547440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.